Advertisement

2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk

      Ankle–brachial index

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Catapano A.L.
        • Graham I.
        • De Backer G.
        • Wiklund O.
        • Chapman M.J.
        • Drexel H.
        • Hoes A.W.
        • Jennings C.S.
        • Landmesser U.
        • Pedersen T.R.
        • Reiner Z.
        • Riccardi G.
        • Taskinen M.R.
        • Tokgozoglu L.
        • Verschuren W.M.M.
        • Vlachopoulos C.
        • Wood D.A.
        • Zamorano J.L.
        • Cooney M.T.
        • ESC Scientific Document Group
        ESC/EAS Guidelines for the management of dyslipidaemias.
        Eur. Heart J. 2016; 37 (2016): 2999-3058
        • Ference B.A.
        • Ginsberg H.N.
        • Graham I.
        • Ray K.K.
        • Packard C.J.
        • Bruckert E.
        • Hegele R.A.
        • Krauss R.M.
        • Raal F.J.
        • Schunkert H.
        • Watts G.F.
        • Boren J.
        • Fazio S.
        • Horton J.D.
        • Masana L.
        • Nicholls S.J.
        • Nordestgaard B.G.
        • van de Sluis B.
        • Taskinen M.R.
        • Tokgozoglu L.
        • Landmesser U.
        • Laufs U.
        • Wiklund O.
        • Stock J.K.
        • Chapman M.J.
        • Catapano A.L.
        Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel.
        Eur. Heart J. 2017; 38: 2459-2472
        • Townsend N.
        • Nichols M.
        • Scarborough P.
        • Rayner M.
        Cardiovascular disease in Europe--epidemiological update 2015.
        Eur. Heart J. 2015; 36: 2696-2705
        • Cooney M.T.
        • Dudina A.
        • Whincup P.
        • Capewell S.
        • Menotti A.
        • Jousilahti P.
        • Njolstad I.
        • Oganov R.
        • Thomsen T.
        • Tverdal A.
        • Wedel H.
        • Wilhelmsen L.
        • Graham I.
        • Investigators S.C.O.R.E.
        Re-evaluating the Rose approach: comparative benefits of the population and high-risk preventive strategies.
        Eur. J. Cardiovasc. Prev. Rehabil. 2009; 16: 541-549
        • World Health Organization
        Global status report on noncommunicable diseases 2014.
        World Health Organization. 2014; (Geneva, Switzerland)
        • Cooney M.T.
        • Dudina A.L.
        • Graham I.M.
        Value and limitations of existing scores for the assessment of cardiovascular risk: a review for clinicians.
        J. Am. Coll. Cardiol. 2009; 54: 1209-1227
        • Hajifathalian K.
        • Ueda P.
        • Lu Y.
        • Woodward M.
        • Ahmadvand A.
        • Aguilar-Salinas C.A.
        • Azizi F.
        • Cifkova R.
        • Di Cesare M.
        • Eriksen L.
        • Farzadfar F.
        • Ikeda N.
        • Khalili D.
        • Khang Y.H.
        • Lanska V.
        • Leon-Munoz L.
        • Magliano D.
        • Msyamboza K.P.
        • Oh K.
        • Rodriguez-Artalejo F.
        • Rojas-Martinez R.
        • Shaw J.E.
        • Stevens G.A.
        • Tolstrup J.
        • Zhou B.
        • Salomon J.A.
        • Ezzati M.
        • Danaei G.
        A novel risk score to predict cardiovascular disease risk in national populations (Globorisk): a pooled analysis of prospective cohorts and health examination surveys.
        Lancet Diabetes Endocrinol. 2015; 3: 339-355
        • Cooney M.T.
        • Dudina A.
        • D'Agostino R.
        • Graham I.M.
        Cardiovascular risk-estimation systems in primary prevention: do they differ? Do they make a difference? Can we see the future?.
        Circulation. 2010; 122: 300-310
        • Perk J.
        • De Backer G.
        • Gohlke H.
        • Graham I.
        • Reiner Z.
        • Verschuren M.
        • Albus C.
        • Benlian P.
        • Boysen G.
        • Cifkova R.
        • Deaton C.
        • Ebrahim S.
        • Fisher M.
        • Germano G.
        • Hobbs R.
        • Hoes A.
        • Karadeniz S.
        • Mezzani A.
        • Prescott E.
        • Ryden L.
        • Scherer M.
        • Syvanne M.
        • Scholte op Reimer W.J.
        • Vrints C.
        • Wood D.
        • Zamorano J.L.
        • Zannad F.
        European association for cardiovascular prevention & rehabilitation; ESC Committee for practice guidelines (CPG). European guidelines on cardiovascular disease prevention in clinical practice (version 2012). The fifth Joint task force of the European society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts).
        Eur. Heart J. 2012; 33: 1635-1701
        • Piepoli M.F.
        • Hoes A.W.
        • Agewall S.
        • Albus C.
        • Brotons C.
        • Catapano A.L.
        • Cooney M.T.
        • Corra U.
        • Cosyns B.
        • Deaton C.
        • Graham I.
        • Hall M.S.
        • Hobbs F.D.
        • Lochen M.L.
        • Lollgen H.
        • Marques-Vidal P.
        • Perk J.
        • Prescott E.
        • Redon J.
        • Richter D.J.
        • Sattar N.
        • Smulders Y.
        • Tiberi M.
        • van der Worp H.B.
        • van Dis I.
        • Verschuren W.M.
        • Authors/Task Force M.
        European guidelines on cardiovascular disease prevention in clinical practice: the sixth Joint task force of the European society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European association for cardiovascular prevention & rehabilitation (EACPR).
        Eur. Heart J. 2016; 37 (2016): 2315-2381
        • Cooney M.T.
        • Selmer R.
        • Lindman A.
        • Tverdal A.
        • Menotti A.
        • Thomsen T.
        • DeBacker G.
        • De Bacquer D.
        • Tell G.S.
        • Njolstad I.
        • Graham I.M.
        • SCORE and CONOR investigators
        Cardiovascular risk estimation in older persons: SCORE O.P.
        Eur J Prev Cardiol. 2016; 23: 1093-1103
        • Berry J.D.
        • Dyer A.
        • Cai X.
        • Garside D.B.
        • Ning H.
        • Thomas A.
        • Greenland P.
        • Van Horn L.
        • Tracy R.P.
        • Lloyd-Jones D.M.
        Lifetime risks of cardiovascular disease.
        N. Engl. J. Med. 2012; 366: 321-329
        • Foster H.M.E.
        • Celis-Morales C.A.
        • Nicholl B.I.
        • Petermann-Rocha F.
        • Pell J.P.
        • Gill J.M.R.
        • O'Donnell C.A.
        • Mair F.S.
        The effect of socioeconomic deprivation on the association between an extended measurement of unhealthy lifestyle factors and health outcomes: a prospective analysis of the UK Biobank cohort.
        Lancet Public Health. 2018; 3: e576-e585
        • Kavousi M.
        • Elias-Smale S.
        • Rutten J.H.
        • Leening M.J.
        • Vliegenthart R.
        • Verwoert G.C.
        • Krestin G.P.
        • Oudkerk M.
        • de Maat M.P.
        • Leebeek F.W.
        • Mattace-Raso F.U.
        • Lindemans J.
        • Hofman A.
        • Steyerberg E.W.
        • van der Lugt A.
        • van den Meiracker A.H.
        • Witteman J.C.
        Evaluation of newer risk markers for coronary heart disease risk classification: a cohort study.
        Ann. Intern. Med. 2012; 156: 438-444
        • Vlachopoulos C.
        • Xaplanteris P.
        • Aboyans V.
        • Brodmann M.
        • Cifkova R.
        • Cosentino F.
        • De Carlo M.
        • Gallino A.
        • Landmesser U.
        • Laurent S.
        • Lekakis J.
        • Mikhailidis D.P.
        • Naka K.K.
        • Protogerou A.D.
        • Rizzoni D.
        • Schmidt-Trucksass A.
        • Van Bortel L.
        • Weber T.
        • Yamashina A.
        • Zimlichman R.
        • Boutouyrie P.
        • Cockcroft J.
        • O'Rourke M.
        • Park J.B.
        • Schillaci G.
        • Sillesen H.
        • Townsend R.R.
        The role of vascular biomarkers for primary and secondary prevention. A position paper from the European Society of Cardiology Working Group on peripheral circulation: endorsed by the Association for Research into Arterial Structure and Physiology (ARTERY) Society.
        Atherosclerosis. 2015; 241: 507-532
        • Yeboah J.
        • McClelland R.L.
        • Polonsky T.S.
        • Burke G.L.
        • Sibley C.T.
        • O'Leary D.
        • Carr J.J.
        • Goff D.C.
        • Greenland P.
        • Herrington D.M.
        Comparison of novel risk markers for improvement in cardiovascular risk assessment in intermediate-risk individuals.
        J. Am. Med. Assoc. 2012; 308: 788-795
        • Madsen C.M.
        • Varbo A.
        • Nordestgaard B.G.
        Extreme high high-density lipoprotein cholesterol is paradoxically associated with high mortality in men and women: two prospective cohort studies.
        Eur. Heart J. 2017; 38: 2478-2486
        • Mortensen M.B.
        • Falk E.
        • Li D.
        • Nasir K.
        • Blaha M.J.
        • Sandfort V.
        • Rodriguez C.J.
        • Ouyang P.
        • Budoff M.
        Statin trials, cardiovascular events, and coronary artery calcification: implications for a trial-based approach to statin therapy in MESA.
        JACC Cardiovasc Imaging. 2018; 11: 221-230
        • Lin J.S.
        • Evans C.V.
        • Johnson E.
        • Redmond N.
        • Coppola E.L.
        • Smith N.
        Nontraditional risk factors in cardiovascular disease risk assessment: updated evidence report and systematic review for the US Preventive Services Task Force.
        J. Am. Med. Assoc. 2018; 320: 281-297
        • Baber U.
        • Mehran R.
        • Sartori S.
        • Schoos M.M.
        • Sillesen H.
        • Muntendam P.
        • Garcia M.J.
        • Gregson J.
        • Pocock S.
        • Falk E.
        • Fuster V.
        Prevalence, impact, and predictive value of detecting subclinical coronary and carotid atherosclerosis in asymptomatic adults: the BioImage study.
        J. Am. Coll. Cardiol. 2015; 65: 1065-1074
        • McDermott M.M.
        • Kramer C.M.
        • Tian L.
        • Carr J.
        • Guralnik J.M.
        • Polonsky T.
        • Carroll T.
        • Kibbe M.
        • Criqui M.H.
        • Ferrucci L.
        • Zhao L.
        • Hippe D.S.
        • Wilkins J.
        • Xu D.
        • Liao Y.
        • McCarthy W.
        • Yuan C.
        Plaque composition in the proximal superficial femoral artery and peripheral artery disease events.
        JACC Cardiovasc Imaging. 2017; 10: 1003-1012
        • Sillesen H.
        • Sartori S.
        • Sandholt B.
        • Baber U.
        • Mehran R.
        • Fuster V.
        Carotid plaque thickness and carotid plaque burden predict future cardiovascular events in asymptomatic adult Americans.
        Eur Heart J Cardiovasc Imaging. 2018; 19: 1042-1050
        • Perrone-Filardi P.
        • Achenbach S.
        • Mohlenkamp S.
        • Reiner Z.
        • Sambuceti G.
        • Schuijf J.D.
        • Van der Wall E.
        • Kaufmann P.A.
        • Knuuti J.
        • Schroeder S.
        • Zellweger M.J.
        Cardiac computed tomography and myocardial perfusion scintigraphy for risk stratification in asymptomatic individuals without known cardiovascular disease: a position statement of the Working Group on Nuclear Cardiology and Cardiac CT of the European Society of Cardiology.
        Eur. Heart J. 2011; 32 (1993a, 1993b): 1986-1993
        • Den Ruijter H.M.
        • Peters S.A.
        • Anderson T.J.
        • Britton A.R.
        • Dekker J.M.
        • Eijkemans M.J.
        • Engstrom G.
        • Evans G.W.
        • de Graaf J.
        • Grobbee D.E.
        • Hedblad B.
        • Hofman A.
        • Holewijn S.
        • Ikeda A.
        • Kavousi M.
        • Kitagawa K.
        • Kitamura A.
        • Koffijberg H.
        • Lonn E.M.
        • Lorenz M.W.
        • Mathiesen E.B.
        • Nijpels G.
        • Okazaki S.
        • O'Leary D.H.
        • Polak J.F.
        • Price J.F.
        • Robertson C.
        • Rembold C.M.
        • Rosvall M.
        • Rundek T.
        • Salonen J.T.
        • Sitzer M.
        • Stehouwer C.D.
        • Witteman J.C.
        • Moons K.G.
        • Bots M.L.
        Common carotid intima-media thickness measurements in cardiovascular risk prediction: a meta-analysis.
        J. Am. Med. Assoc. 2012; 308: 796-803
        • Lorenz M.W.
        • Schaefer C.
        • Steinmetz H.
        • Sitzer M.
        Is carotid intima media thickness useful for individual prediction of cardiovascular risk? Ten-year results from the Carotid Atherosclerosis Progression Study (CAPS).
        Eur. Heart J. 2010; 31: 2041-2048
        • Garg P.K.
        • Jorgensen N.W.
        • McClelland R.L.
        • Leigh J.A.
        • Greenland P.
        • Blaha M.J.
        • Yoon A.J.
        • Wong N.D.
        • Yeboah J.
        • Budoff M.J.
        Use of coronary artery calcium testing to improve coronary heart disease risk assessment in a lung cancer screening population: the Multi-Ethnic Study of Atherosclerosis (MESA).
        J Cardiovasc Comput Tomogr. 2018; 12: 493-499
        • Hong J.C.
        • Blankstein R.
        • Shaw L.J.
        • Padula W.V.
        • Arrieta A.
        • Fialkow J.A.
        • Blumenthal R.S.
        • Blaha M.J.
        • Krumholz H.M.
        • Nasir K.
        Implications of coronary artery calcium testing for treatment decisions among statin candidates according to the ACC/AHA cholesterol management guidelines: a cost-effectiveness analysis.
        JACC Cardiovasc Imaging. 2017; 10: 938-952
        • Cho I.
        • Al'Aref S.J.
        • Berger A.B.O.H.
        • Gransar H.
        • Valenti V.
        • Lin F.Y.
        • Achenbach S.
        • Berman D.S.
        • Budoff M.J.
        • Callister T.Q.
        • Al-Mallah M.H.
        • Cademartiri F.
        • Chinnaiyan K.
        • Chow B.J.W.
        • DeLago A.
        • Villines T.C.
        • Hadamitzky M.
        • Hausleiter J.
        • Leipsic J.
        • Shaw L.J.
        • Kaufmann P.A.
        • Feuchtner G.
        • Kim Y.J.
        • Maffei E.
        • Raff G.
        • Pontone G.
        • Andreini D.
        • Marques H.
        • Rubinshtein R.
        • Chang H.J.
        • Min J.K.
        Prognostic value of coronary computed tomographic angiography findings in asymptomatic individuals: a 6-year follow-up from the prospective multicentre international CONFIRM study.
        Eur. Heart J. 2018; 39: 934-941
        • Kavousi M.
        • Desai C.S.
        • Ayers C.
        • Blumenthal R.S.
        • Budoff M.J.
        • Mahabadi A.A.
        • Ikram M.A.
        • van der Lugt A.
        • Hofman A.
        • Erbel R.
        • Khera A.
        • Geisel M.H.
        • Jockel K.H.
        • Lehmann N.
        • Hoffmann U.
        • O'Donnell C.J.
        • Massaro J.M.
        • Liu K.
        • Mohlenkamp S.
        • Ning H.
        • Franco O.H.
        • Greenland P.
        Prevalence and prognostic implications of coronary artery calcification in low-risk women: a meta-analysis.
        J. Am. Med. Assoc. 2016; 316: 2126-2134
        • Boekholdt S.M.
        • Hovingh G.K.
        • Mora S.
        • Arsenault B.J.
        • Amarenco P.
        • Pedersen T.R.
        • LaRosa J.C.
        • Waters D.D.
        • DeMicco D.A.
        • Simes R.J.
        • Keech A.C.
        • Colquhoun D.
        • Hitman G.A.
        • Betteridge D.J.
        • Clearfield M.B.
        • Downs J.R.
        • Colhoun H.M.
        • Gotto Jr., A.M.
        • Ridker P.M.
        • Grundy S.M.
        • Kastelein J.J.
        Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials.
        J. Am. Coll. Cardiol. 2014; 64: 485-494
        • Brugts J.J.
        • Yetgin T.
        • Hoeks S.E.
        • Gotto A.M.
        • Shepherd J.
        • Westendorp R.G.
        • de Craen A.J.
        • Knopp R.H.
        • Nakamura H.
        • Ridker P.
        • van Domburg R.
        • Deckers J.W.
        The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials.
        BMJ. 2009; 338: b2376
        • Cannon C.P.
        • Blazing M.A.
        • Giugliano R.P.
        • McCagg A.
        • White J.A.
        • Theroux P.
        • Darius H.
        • Lewis B.S.
        • Ophuis T.O.
        • Jukema J.W.
        • De Ferrari G.M.
        • Ruzyllo W.
        • De Lucca P.
        • Im K.
        • Bohula E.A.
        • Reist C.
        • Wiviott S.D.
        • Tershakovec A.M.
        • Musliner T.A.
        • Braunwald E.
        • Califf R.M.
        • IMPROVE-IT Investigators
        Ezetimibe added to statin therapy after acute coronary syndromes.
        N. Engl. J. Med. 2015; 372: 2387-2397
        • Cholesterol Treatment Trialists Collaboration
        • Baigent C.
        • Blackwell L.
        • Emberson J.
        • Holland L.E.
        • Reith C.
        • Bhala N.
        • Peto R.
        • Barnes E.H.
        • Keech A.
        • Simes J.
        • Collins R.
        Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials.
        Lancet. 2010; 376: 1670-1681
        • Cholesterol Treatment Trialists Collaboration
        • Fulcher J.
        • O'Connell R.
        • Voysey M.
        • Emberson J.
        • Blackwell L.
        • Mihaylova B.
        • Simes J.
        • Collins R.
        • Kirby A.
        • Colhoun H.
        • Braunwald E.
        • La Rosa J.
        • Pedersen T.R.
        • Tonkin A.
        • Davis B.
        • Sleight P.
        • Franzosi M.G.
        • Baigent C.
        • Keech A.
        Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials.
        Lancet. 2015; 385: 1397-1405
        • Cholesterol Treatment Trialists Collaboration
        • Mihaylova B.
        • Emberson J.
        • Blackwell L.
        • Keech A.
        • Simes J.
        • Barnes E.H.
        • Voysey M.
        • Gray A.
        • Collins R.
        • Baigent C.
        The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials.
        Lancet. 2012; 380: 581-590
        • Hegele R.A.
        • Ginsberg H.N.
        • Chapman M.J.
        • Nordestgaard B.G.
        • Kuivenhoven J.A.
        • Averna M.
        • Boren J.
        • Bruckert E.
        • Catapano A.L.
        • Descamps O.S.
        • Hovingh G.K.
        • Humphries S.E.
        • Kovanen P.T.
        • Masana L.
        • Pajukanta P.
        • Parhofer K.G.
        • Raal F.J.
        • Ray K.K.
        • Santos R.D.
        • Stalenhoef A.F.
        • Stroes E.
        • Taskinen M.R.
        • Tybjaerg-Hansen A.
        • Watts G.F.
        • Wiklund O.
        European Atherosclerosis Society Consensus Panel. The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management.
        Lancet Diabetes Endocrinol. 2014; 2: 655-666
        • Mills E.J.
        • Rachlis B.
        • Wu P.
        • Devereaux P.J.
        • Arora P.
        • Perri D.
        Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients.
        J. Am. Coll. Cardiol. 2008; 52: 1769-1781
        • Pedersen T.R.
        • Faergeman O.
        • Kastelein J.J.
        • Olsson A.G.
        • Tikkanen M.J.
        • Holme I.
        • Larsen M.L.
        • Bendiksen F.S.
        • Lindahl C.
        • Szarek M.
        • Tsai J.
        Incremental Decrease in End Points through Aggressive Lipid Lowering (IDEAL) Study Group. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial.
        J. Am. Med. Assoc. 2005; 294: 2437-2445
        • Stone N.J.
        • Robinson J.G.
        • Lichtenstein A.H.
        • Bairey Merz C.N.
        • Blum C.B.
        • Eckel R.H.
        • Goldberg A.C.
        • Gordon D.
        • Levy D.
        • Lloyd-Jones D.M.
        • McBride P.
        • Schwartz J.S.
        • Shero S.T.
        • Smith Jr., S.C.
        • Watson K.
        • Wilson P.W.
        • Eddleman K.M.
        • Jarrett N.M.
        • LaBresh K.
        • Nevo L.
        • Wnek J.
        • Anderson J.L.
        • Halperin J.L.
        • Albert N.M.
        • Bozkurt B.
        • Brindis R.G.
        • Curtis L.H.
        • DeMets D.
        • Hochman J.S.
        • Kovacs R.J.
        • Ohman E.M.
        • Pressler S.J.
        • Sellke F.W.
        • Shen W.K.
        • Smith Jr., S.C.
        • Tomaselli G.F.
        • American College of Cardiology/American Heart Association Task Force on Practice Guidelines
        ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.
        Circulation. 2013; 129 (2014): S1-S45
        • Vallejo-Vaz A.J.
        • Robertson M.
        • Catapano A.L.
        • Watts G.F.
        • Kastelein J.J.
        • Packard C.J.
        • Ford I.
        • Ray K.K.
        Low-density lipoprotein cholesterol lowering for the primary prevention of cardiovascular disease among men with primary elevations of low-density lipoprotein cholesterol levels of 190 mg/dL or above: analyses from the WOSCOPS (West of Scotland Coronary Prevention Study) 5-year randomized trial and 20-year observational follow-up.
        Circulation. 2017; 136: 1878-1891
        • Tabas I.
        • Williams K.J.
        • Boren J.
        Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications.
        Circulation. 2007; 116: 1832-1844
        • Boren J.
        • Williams K.J.
        The central role of arterial retention of cholesterol-rich apolipoprotein-B-containing lipoproteins in the pathogenesis of atherosclerosis: a triumph of simplicity.
        Curr. Opin. Lipidol. 2016; 27: 473-483
        • Ference B.A.
        • Graham I.
        • Tokgozoglu L.
        • Catapano A.L.
        Impact of lipids on cardiovascular health: JACC health promotion series.
        J. Am. Coll. Cardiol. 2018; 72: 1141-1156
        • Emerging Risk Factors Collaboration
        • Di Angelantonio E.
        • Gao P.
        • Pennells L.
        • Kaptoge S.
        • Caslake M.
        • Thompson A.
        • Butterworth A.S.
        • Sarwar N.
        • Wormser D.
        • Saleheen D.
        • Ballantyne C.M.
        • Psaty B.M.
        • Sundstrom J.
        • Ridker P.M.
        • Nagel D.
        • Gillum R.F.
        • Ford I.
        • Ducimetiere P.
        • Kiechl S.
        • Koenig W.
        • Dullaart R.P.
        • Assmann G.
        • D'Agostino Sr., R.B.
        • Dagenais G.R.
        • Cooper J.A.
        • Kromhout D.
        • Onat A.
        • Tipping R.W.
        • Gomez-de-la-Camara A.
        • Rosengren A.
        • Sutherland S.E.
        • Gallacher J.
        • Fowkes F.G.
        • Casiglia E.
        • Hofman A.
        • Salomaa V.
        • Barrett-Connor E.
        • Clarke R.
        • Brunner E.
        • Jukema J.W.
        • Simons L.A.
        • Sandhu M.
        • Wareham N.J.
        • Khaw K.T.
        • Kauhanen J.
        • Salonen JT.
        • Howard W.J.
        • Nordestgaard B.G.
        • Wood A.M.
        • Thompson S.G.
        • Boekholdt S.M.
        • Sattar N.
        • Packard C.
        • Gudnason V.
        • Danesh J.
        Lipid-related markers and cardiovascular disease prediction.
        J. Am. Med. Assoc. 2012; 307: 2499-2506
        • Willer C.J.
        • Schmidt E.M.
        • Sengupta S.
        • Peloso G.M.
        • Gustafsson S.
        • Kanoni S.
        • Ganna A.
        • Chen J.
        • Buchkovich M.L.
        • Mora S.
        • Beckmann J.S.
        • Bragg-Gresham J.L.
        • Chang H.Y.
        • Demirkan A.
        • Den Hertog H.M.
        • Do R.
        • Donnelly L.A.
        • Ehret G.B.
        • Esko T.
        • Feitosa M.F.
        • Ferreira T.
        • Fischer K.
        • Fontanillas P.
        • Fraser R.M.
        • Freitag D.F.
        • Gurdasani D.
        • Heikkila K.
        • Hypponen E.
        • Isaacs A.
        • Jackson A.U.
        • Johansson A.
        • Johnson T.
        • Kaakinen M.
        • Kettunen J.
        • Kleber M.E.
        • Li X.
        • Luan J.
        • Lyytikainen L.P.
        • Magnusson P.K.E.
        • Mangino M.
        • Mihailov E.
        • Montasser M.E.
        • Muller-Nurasyid M.
        • Nolte I.M.
        • O'Connell J.R.
        • Palmer C.D.
        • Perola M.
        • Petersen A.K.
        • Sanna S.
        • Saxena R.
        • Service S.K.
        • Shah S.
        • Shungin D.
        • Sidore C.
        • Song C.
        • Strawbridge R.J.
        • Surakka I.
        • Tanaka T.
        • Teslovich T.M.
        • Thorleifsson G.
        • Van den Herik E.G.
        • Voight B.F.
        • Volcik K.A.
        • Waite L.L.
        • Wong A.
        • Wu Y.
        • Zhang W.
        • Absher D.
        • Asiki G.
        • Barroso I.
        • Been L.F.
        • Bolton J.L.
        • Bonnycastle L.L.
        • Brambilla P.
        • Burnett M.S.
        • Cesana G.
        • Dimitriou M.
        • Doney A.S.F.
        • Doring A.
        • Elliott P.
        • Epstein S.E.
        • Ingi Eyjolfsson G.
        • Gigante B.
        • Goodarzi M.O.
        • Grallert H.
        • Gravito M.L.
        • Groves C.J.
        • Hallmans G.
        • Hartikainen A.L.
        • Hayward C.
        • Hernandez D.
        • Hicks A.A.
        • Holm H.
        • Hung Y.J.
        • Illig T.
        • Jones M.R.
        • Kaleebu P.
        • Kastelein J.J.P.
        • Khaw K.T.
        • Kim E.
        • Klopp N.
        • Komulainen P.
        • Kumari M.
        • Langenberg C.
        • Lehtimaki T.
        • Lin S.Y.
        • Lindstrom J.
        • Loos R.J.F.
        • Mach F.
        • McArdle W.L.
        • Meisinger C.
        • Mitchell B.D.
        • Muller G.
        • Nagaraja R.
        • Narisu N.
        • Nieminen T.V.M.
        • Nsubuga R.N.
        • Olafsson I.
        • Ong K.K.
        • Palotie A.
        • Papamarkou T.
        • Pomilla C.
        • Pouta A.
        • Rader D.J.
        • Reilly M.P.
        • Ridker P.M.
        • Rivadeneira F.
        • Rudan I.
        • Ruokonen A.
        • Samani N.
        • Scharnagl H.
        • Seeley J.
        • Silander K.
        • Stancakova A.
        • Stirrups K.
        • Swift A.J.
        • Tiret L.
        • Uitterlinden A.G.
        • van Pelt L.J.
        • Vedantam S.
        • Wainwright N.
        • Wijmenga C.
        • Wild S.H.
        • Willemsen G.
        • Wilsgaard T.
        • Wilson J.F.
        • Young E.H.
        • Zhao J.H.
        • Adair L.S.
        • Arveiler D.
        • Assimes T.L.
        • Bandinelli S.
        • Bennett F.
        • Bochud M.
        • Boehm B.O.
        • Boomsma D.I.
        • Borecki I.B.
        • Bornstein S.R.
        • Bovet P.
        • Burnier M.
        • Campbell H.
        • Chakravarti A.
        • Chambers J.C.
        • Chen Y.I.
        • Collins F.S.
        • Cooper R.S.
        • Danesh J.
        • Dedoussis G.
        • de Faire U.
        • Feranil A.B.
        • Ferrieres J.
        • Ferrucci L.
        • Freimer N.B.
        • Gieger C.
        • Groop L.C.
        • Gudnason V.
        • Gyllensten U.
        • Hamsten A.
        • Harris T.B.
        • Hingorani A.
        • Hirschhorn J.N.
        • Hofman A.
        • Hovingh G.K.
        • Hsiung C.A.
        • Humphries S.E.
        • Hunt S.C.
        • Hveem K.
        • Iribarren C.
        • Jarvelin M.R.
        • Jula A.
        • Kahonen M.
        • Kaprio J.
        • Kesaniemi A.
        • Kivimaki M.
        • Kooner J.S.
        • Koudstaal P.J.
        • Krauss R.M.
        • Kuh D.
        • Kuusisto J.
        • Kyvik K.O.
        • Laakso M.
        • Lakka T.A.
        • Lind L.
        • Lindgren C.M.
        • Martin N.G.
        • Marz W.
        • McCarthy M.I.
        • McKenzie C.A.
        • Meneton P.
        • Metspalu A.
        • Moilanen L.
        • Morris A.D.
        • Munroe P.B.
        • Njolstad I.
        • Pedersen N.L.
        • Power C.
        • Pramstaller P.P.
        • Price J.F.
        • Psaty B.M.
        • Quertermous T.
        • Rauramaa R.
        • Saleheen D.
        • Salomaa V.
        • Sanghera D.K.
        • Saramies J.
        • Schwarz P.E.H.
        • Sheu W.H.
        • Shuldiner A.R.
        • Siegbahn A.
        • Spector T.D.
        • Stefansson K.
        • Strachan D.P.
        • Tayo B.O.
        • Tremoli E.
        • Tuomilehto J.
        • Uusitupa M.
        • van Duijn C.M.
        • Vollenweider P.
        • Wallentin L.
        • Wareham N.J.
        • Whitfield J.B.
        • Wolffenbuttel B.H.R.
        • Ordovas J.M.
        • Boerwinkle E.
        • Palmer C.N.A.
        • Thorsteinsdottir U.
        • Chasman D.I.
        • Rotter J.I.
        • Franks P.W.
        • Ripatti S.
        • Cupples L.A.
        • Sandhu M.S.
        • Rich S.S.
        • Boehnke M.
        • Deloukas P.
        • Kathiresan S.
        • Mohlke K.L.
        • Ingelsson E.
        • Abecasis G.R.
        Global Lipids Genetics Consortium. Discovery and refinement of loci associated with lipid levels.
        Nat. Genet. 2013; 45: 1274-1283
        • Nikpay M.
        • Goel A.
        • Won H.H.
        • Hall L.M.
        • Willenborg C.
        • Kanoni S.
        • Saleheen D.
        • Kyriakou T.
        • Nelson C.P.
        • Hopewell J.C.
        • Webb T.R.
        • Zeng L.
        • Dehghan A.
        • Alver M.
        • Armasu S.M.
        • Auro K.
        • Bjonnes A.
        • Chasman D.I.
        • Chen S.
        • Ford I.
        • Franceschini N.
        • Gieger C.
        • Grace C.
        • Gustafsson S.
        • Huang J.
        • Hwang S.J.
        • Kim Y.K.
        • Kleber M.E.
        • Lau K.W.
        • Lu X.
        • Lu Y.
        • Lyytikainen L.P.
        • Mihailov E.
        • Morrison A.C.
        • Pervjakova N.
        • Qu L.
        • Rose L.M.
        • Salfati E.
        • Saxena R.
        • Scholz M.
        • Smith A.V.
        • Tikkanen E.
        • Uitterlinden A.
        • Yang X.
        • Zhang W.
        • Zhao W.
        • de Andrade M.
        • de Vries P.S.
        • van Zuydam N.R.
        • Anand S.S.
        • Bertram L.
        • Beutner F.
        • Dedoussis G.
        • Frossard P.
        • Gauguier D.
        • Goodall A.H.
        • Gottesman O.
        • Haber M.
        • Han B.G.
        • Huang J.
        • Jalilzadeh S.
        • Kessler T.
        • Konig I.R.
        • Lannfelt L.
        • Lieb W.
        • Lind L.
        • Lindgren C.M.
        • Lokki M.L.
        • Magnusson P.K.
        • Mallick N.H.
        • Mehra N.
        • Meitinger T.
        • Memon F.U.
        • Morris A.P.
        • Nieminen M.S.
        • Pedersen N.L.
        • Peters A.
        • Rallidis L.S.
        • Rasheed A.
        • Samuel M.
        • Shah S.H.
        • Sinisalo J.
        • Stirrups K.E.
        • Trompet S.
        • Wang L.
        • Zaman K.S.
        • Ardissino D.
        • Boerwinkle E.
        • Borecki I.B.
        • Bottinger E.P.
        • Buring J.E.
        • Chambers J.C.
        • Collins R.
        • Cupples L.A.
        • Danesh J.
        • Demuth I.
        • Elosua R.
        • Epstein S.E.
        • Esko T.
        • Feitosa M.F.
        • Franco O.H.
        • Franzosi M.G.
        • Granger C.B.
        • Gu D.
        • Gudnason V.
        • Hall A.S.
        • Hamsten A.
        • Harris T.B.
        • Hazen S.L.
        • Hengstenberg C.
        • Hofman A.
        • Ingelsson E.
        • Iribarren C.
        • Jukema J.W.
        • Karhunen P.J.
        • Kim B.J.
        • Kooner J.S.
        • Kullo I.J.
        • Lehtimaki T.
        • Loos R.J.F.
        • Melander O.
        • Metspalu A.
        • Marz W.
        • Palmer C.N.
        • Perola M.
        • Quertermous T.
        • Rader D.J.
        • Ridker P.M.
        • Ripatti S.
        • Roberts R.
        • Salomaa V.
        • Sanghera D.K.
        • Schwartz S.M.
        • Seedorf U.
        • Stewart A.F.
        • Stott D.J.
        • Thiery J.
        • Zalloua P.A.
        • O'Donnell C.J.
        • Reilly M.P.
        • Assimes T.L.
        • Thompson J.R.
        • Erdmann J.
        • Clarke R.
        • Watkins H.
        • Kathiresan S.
        • McPherson R.
        • Deloukas P.
        • Schunkert H.
        • Samani N.J.
        • Farrall M.
        A comprehensive 1,000 Genomes-based genome-wide association meta-analysis of coronary artery disease.
        Nat. Genet. 2015; 47: 1121-1130
        • Ference B.A.
        • Yoo W.
        • Alesh I.
        • Mahajan N.
        • Mirowska K.K.
        • Mewada A.
        • Kahn J.
        • Afonso L.
        • Williams Sr., K.A.
        • Flack J.M.
        Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis.
        J. Am. Coll. Cardiol. 2012; 60: 2631-2639
        • Holmes M.V.
        • Asselbergs F.W.
        • Palmer T.M.
        • Drenos F.
        • Lanktree M.B.
        • Nelson C.P.
        • Dale C.E.
        • Padmanabhan S.
        • Finan C.
        • Swerdlow D.I.
        • Tragante V.
        • van Iperen E.P.
        • Sivapalaratnam S.
        • Shah S.
        • Elbers C.C.
        • Shah T.
        • Engmann J.
        • Giambartolomei C.
        • White J.
        • Zabaneh D.
        • Sofat R.
        • McLachlan S.
        • consortium U.
        • Doevendans P.A.
        • Balmforth A.J.
        • Hall A.S.
        • North K.E.
        • Almoguera B.
        • Hoogeveen R.C.
        • Cushman M.
        • Fornage M.
        • Patel S.R.
        • Redline S.
        • Siscovick D.S.
        • Tsai M.Y.
        • Karczewski K.J.
        • Hofker M.H.
        • Verschuren W.M.
        • Bots M.L.
        • van der Schouw Y.T.
        • Melander O.
        • Dominiczak A.F.
        • Morris R.
        • Ben-Shlomo Y.
        • Price J.
        • Kumari M.
        • Baumert J.
        • Peters A.
        • Thorand B.
        • Koenig W.
        • Gaunt T.R.
        • Humphries S.E.
        • Clarke R.
        • Watkins H.
        • Farrall M.
        • Wilson J.G.
        • Rich S.S.
        • de Bakker P.I.
        • Lange L.A.
        • Davey Smith G.
        • Reiner A.P.
        • Talmud P.J.
        • Kivimaki M.
        • Lawlor D.A.
        • Dudbridge F.
        • Samani N.J.
        • Keating B.J.
        • Hingorani A.D.
        • Casas J.P.
        Mendelian randomization of blood lipids for coronary heart disease.
        Eur. Heart J. 2015; 36: 539-550
        • Silverman M.G.
        • Ference B.A.
        • Im K.
        • Wiviott S.D.
        • Giugliano R.P.
        • Grundy S.M.
        • Braunwald E.
        • Sabatine M.S.
        Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis.
        J. Am. Med. Assoc. 2016; 316: 1289-1297
        • Baigent C.
        • Keech A.
        • Kearney P.M.
        • Blackwell L.
        • Buck G.
        • Pollicino C.
        • Kirby A.
        • Sourjina T.
        • Peto R.
        • Collins R.
        • Simes R.
        • Cholesterol Treatment Trialists' (CTT) Collaborators
        Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.
        Lancet. 2005; 366: 1267-1278
        • Cohen J.C.
        • Boerwinkle E.
        • Mosley Jr., T.H.
        • Hobbs H.H.
        Sequence variations in PCSK9, low LDL, and protection against coronary heart disease.
        N. Engl. J. Med. 2006; 354: 1264-1272
        • Ference B.A.
        • Kastelein J.J.P.
        • Ray K.K.
        • Ginsberg H.N.
        • Chapman M.J.
        • Packard C.J.
        • Laufs U.
        • Oliver-Williams C.
        • Wood A.M.
        • Butterworth A.S.
        • Di Angelantonio E.
        • Danesh J.
        • Nicholls S.J.
        • Bhatt D.L.
        • Sabatine M.S.
        • Catapano A.L.
        Association of triglyceride-lowering LPL variants and LDL-C-lowering LDLR variants with risk of coronary heart disease.
        J. Am. Med. Assoc. 2019; 321: 364-373
        • Ference B.A.
        • Majeed F.
        • Penumetcha R.
        • Flack J.M.
        • Brook R.D.
        Effect of naturally random allocation to lower low-density lipoprotein cholesterol on the risk of coronary heart disease mediated by polymorphisms in NPC1L1, HMGCR, or both: a 2 x 2 factorial Mendelian randomization study.
        J. Am. Coll. Cardiol. 2015; 65: 1552-1561
        • Ference B.A.
        • Robinson J.G.
        • Brook R.D.
        • Catapano A.L.
        • Chapman M.J.
        • Neff D.R.
        • Voros S.
        • Giugliano R.P.
        • Davey Smith G.
        • Fazio S.
        • Sabatine M.S.
        Variation in PCSK9 and HMGCR and risk of cardiovascular disease and diabetes.
        N. Engl. J. Med. 2016; 375: 2144-2153
        • Sarwar N.
        • Sandhu M.S.
        • Ricketts S.L.
        • Butterworth A.S.
        • Di Angelantonio E.
        • Boekholdt S.M.
        • Ouwehand W.
        • Watkins H.
        • Samani N.J.
        • Saleheen D.
        • Lawlor D.
        • Reilly M.P.
        • Hingorani A.D.
        • Talmud P.J.
        • Danesh J.
        • Triglyceride Coronary Disease Genetics Consortium, Emerging Risk Factors Collaboration
        Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies.
        Lancet. 2010; 375: 1634-1639
        • Varbo A.
        • Benn M.
        • Tybjaerg-Hansen A.
        • Jorgensen A.B.
        • Frikke-Schmidt R.
        • Nordestgaard B.G.
        Remnant cholesterol as a causal risk factor for ischemic heart disease.
        J. Am. Coll. Cardiol. 2013; 61: 427-436
        • Lewis G.F.
        • Xiao C.
        • Hegele R.A.
        Hypertriglyceridemia in the genomic era: a new paradigm.
        Endocr. Rev. 2015; 36: 131-147
        • Dron J.S.
        • Hegele R.A.
        Complexity of mechanisms among human proprotein convertase subtilisin-kexin type 9 variants.
        Curr. Opin. Lipidol. 2017; 28: 161-169
        • Prospective Studies Collaboration
        • Lewington S.
        • Whitlock G.
        • Clarke R.
        • Sherliker P.
        • Emberson J.
        • Halsey J.
        • Qizilbash N.
        • Peto R.
        • Collins R.
        Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths.
        Lancet. 2007; 370: 1829-1839
        • Frikke-Schmidt R.
        • Nordestgaard B.G.
        • Stene M.C.
        • Sethi A.A.
        • Remaley A.T.
        • Schnohr P.
        • Grande P.
        • Tybjaerg-Hansen A.
        Association of loss-of-function mutations in the ABCA1 gene with high-density lipoprotein cholesterol levels and risk of ischemic heart disease.
        J. Am. Med. Assoc. 2008; 299: 2524-2532
        • Voight B.F.
        • Peloso G.M.
        • Orho-Melander M.
        • Frikke-Schmidt R.
        • Barbalic M.
        • Jensen M.K.
        • Hindy G.
        • Holm H.
        • Ding E.L.
        • Johnson T.
        • Schunkert H.
        • Samani N.J.
        • Clarke R.
        • Hopewell J.C.
        • Thompson J.F.
        • Li M.
        • Thorleifsson G.
        • Newton-Cheh C.
        • Musunuru K.
        • Pirruccello J.P.
        • Saleheen D.
        • Chen L.
        • Stewart A.
        • Schillert A.
        • Thorsteinsdottir U.
        • Thorgeirsson G.
        • Anand S.
        • Engert J.C.
        • Morgan T.
        • Spertus J.
        • Stoll M.
        • Berger K.
        • Martinelli N.
        • Girelli D.
        • McKeown P.P.
        • Patterson C.C.
        • Epstein S.E.
        • Devaney J.
        • Burnett M.S.
        • Mooser V.
        • Ripatti S.
        • Surakka I.
        • Nieminen M.S.
        • Sinisalo J.
        • Lokki M.L.
        • Perola M.
        • Havulinna A.
        • de Faire U.
        • Gigante B.
        • Ingelsson E.
        • Zeller T.
        • Wild P.
        • de Bakker P.I.
        • Klungel O.H.
        • Maitland-van der Zee A.H.
        • Peters B.J.
        • de Boer A.
        • Grobbee D.E.
        • Kamphuisen P.W.
        • Deneer V.H.
        • Elbers C.C.
        • Onland-Moret N.C.
        • Hofker M.H.
        • Wijmenga C.
        • Verschuren W.M.
        • Boer J.M.
        • van der Schouw Y.T.
        • Rasheed A.
        • Frossard P.
        • Demissie S.
        • Willer C.
        • Do R.
        • Ordovas J.M.
        • Abecasis G.R.
        • Boehnke M.
        • Mohlke K.L.
        • Daly M.J.
        • Guiducci C.
        • Burtt N.P.
        • Surti A.
        • Gonzalez E.
        • Purcell S.
        • Gabriel S.
        • Marrugat J.
        • Peden J.
        • Erdmann J.
        • Diemert P.
        • Willenborg C.
        • Konig I.R.
        • Fischer M.
        • Hengstenberg C.
        • Ziegler A.
        • Buysschaert I.
        • Lambrechts D.
        • Van de Werf F.
        • Fox K.A.
        • El Mokhtari N.E.
        • Rubin D.
        • Schrezenmeir J.
        • Schreiber S.
        • Schafer A.
        • Danesh J.
        • Blankenberg S.
        • Roberts R.
        • McPherson R.
        • Watkins H.
        • Hall A.S.
        • Overvad K.
        • Rimm E.
        • Boerwinkle E.
        • Tybjaerg-Hansen A.
        • Cupples L.A.
        • Reilly M.P.
        • Melander O.
        • Mannucci P.M.
        • Ardissino D.
        • Siscovick D.
        • Elosua R.
        • Stefansson K.
        • O'Donnell C.J.
        • Salomaa V.
        • Rader D.J.
        • Peltonen L.
        • Schwartz S.M.
        • Altshuler D.
        • Kathiresan S.
        Plasma HDL cholesterol and risk of myocardial infarction: a Mendelian randomisation study.
        Lancet. 2012; 380: 572-580
        • Lincoff A.M.
        • Nicholls S.J.
        • Riesmeyer J.S.
        • Barter P.J.
        • Brewer H.B.
        • Fox K.A.A.
        • Gibson C.M.
        • Granger C.
        • Menon V.
        • Montalescot G.
        • Rader D.
        • Tall A.R.
        • McErlean E.
        • Wolski K.
        • Ruotolo G.
        • Vangerow B.
        • Weerakkody G.
        • Goodman S.G.
        • Conde D.
        • McGuire D.K.
        • Nicolau J.C.
        • Leiva-Pons J.L.
        • Pesant Y.
        • Li W.
        • Kandath D.
        • Kouz S.
        • Tahirkheli N.
        • Mason D.
        • Nissen S.E.
        ACCELERATE Investigators. Evacetrapib and cardiovascular outcomes in high-risk vascular disease.
        N. Engl. J. Med. 2017; 376: 1933-1942
        • HPS/TIMI/REVEAL Collaborative Group
        • Bowman L.
        • Hopewell J.C.
        • Chen F.
        • Wallendszus K.
        • Stevens W.
        • Collins R.
        • Wiviott S.D.
        • Cannon C.P.
        • Braunwald E.
        • Sammons E.
        • Landray M.J.
        Effects of anacetrapib in patients with atherosclerotic vascular disease.
        N. Engl. J. Med. 2017; 377: 1217-1227
        • Schwartz G.G.
        • Olsson A.G.
        • Abt M.
        • Ballantyne C.M.
        • Barter P.J.
        • Brumm J.
        • Chaitman B.R.
        • Holme I.M.
        • Kallend D.
        • Leiter L.A.
        • Leitersdorf E.
        • McMurray J.J.
        • Mundl H.
        • Nicholls S.J.
        • Shah P.K.
        • Tardif J.C.
        • Wright R.S.
        • Investigators dal-OUTCOMES.
        Effects of dalcetrapib in patients with a recent acute coronary syndrome.
        N. Engl. J. Med. 2012; 367: 2089-2099
        • Aim-High Investigators
        • Boden W.E.
        • Probstfield J.L.
        • Anderson T.
        • Chaitman B.R.
        • Desvignes-Nickens P.
        • Koprowicz K.
        • McBride R.
        • Teo K.
        • Weintraub W.
        Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.
        N. Engl. J. Med. 2011; 365: 2255-2267
        • Group H.T.C.
        • Landray M.J.
        • Haynes R.
        • Hopewell J.C.
        • Parish S.
        • Aung T.
        • Tomson J.
        • Wallendszus K.
        • Craig M.
        • Jiang L.
        • Collins R.
        • Armitage J.
        Effects of extended-release niacin with laropiprant in high-risk patients.
        N. Engl. J. Med. 2014; 371: 203-212
        • Andrews J.
        • Janssan A.
        • Nguyen T.
        • Pisaniello A.D.
        • Scherer D.J.
        • Kastelein J.J.
        • Merkely B.
        • Nissen S.E.
        • Ray K.
        • Schwartz G.G.
        • Worthley S.G.
        • Keyserling C.
        • Dasseux J.L.
        • Butters J.
        • Girardi J.
        • Miller R.
        • Nicholls S.J.
        Effect of serial infusions of reconstituted high-density lipoprotein (CER-001) on coronary atherosclerosis: rationale and design of the CARAT study.
        Cardiovasc. Diagn. Ther. 2017; 7: 45-51
        • Tardif J.C.
        • Ballantyne C.M.
        • Barter P.
        • Dasseux J.L.
        • Fayad Z.A.
        • Guertin M.C.
        • Kastelein J.J.
        • Keyserling C.
        • Klepp H.
        • Koenig W.
        • L'Allier P.L.
        • Lesperance J.
        • Luscher T.F.
        • Paolini J.F.
        • Tawakol A.
        • Waters D.D.
        Can HDL Infusions Significantly QUicken Atherosclerosis REgression (CHI-SQUARE) Investigators. Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial.
        Eur. Heart J. 2014; 35: 3277-3286
        • Nordestgaard B.G.
        • Langsted A.
        Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology.
        J. Lipid Res. 2016; 57: 1953-1975
        • van der Valk F.M.
        • Bekkering S.
        • Kroon J.
        • Yeang C.
        • Van den Bossche J.
        • van Buul J.D.
        • Ravandi A.
        • Nederveen A.J.
        • Verberne H.J.
        • Scipione C.
        • Nieuwdorp M.
        • Joosten L.A.
        • Netea M.G.
        • Koschinsky M.L.
        • Witztum J.L.
        • Tsimikas S.
        • Riksen N.P.
        • Stroes E.S.
        Oxidized phospholipids on lipoprotein(a) elicit arterial wall inflammation and an inflammatory monocyte response in humans.
        Circulation. 2016; 134: 611-624
        • Nordestgaard B.G.
        • Chapman M.J.
        • Ray K.
        • Borén J.
        • Andreotti F.
        • Watts G.F.
        • Ginsberg H.
        • Amarenco P.
        • Catapano A.
        • Descamps O.S.
        • Fisher E.
        • Kovanen P.T.
        • Kuivenhoven J.A.
        • Lesnik P.
        • Masana L.
        • Reiner Z.
        • Taskinen M.R.
        • Tokgözoglu L.
        • Tybjærg-Hansen A.
        European Atherosclerosis Society Consensus Panel. Lipoprotein(a) as a cardiovascular risk factor: current status.
        Eur. Heart J. 2010; 31: 2844-2853
        • Emerging Risk Factors Collaboration
        • Erqou S.
        • Kaptoge S.
        • Perry P.L.
        • Di Angelantonio E.
        • Thompson A.
        • White I.R.
        • Marcovina S.M.
        • Collins R.
        • Thompson S.G.
        • Danesh J.
        Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality.
        J. Am. Med. Assoc. 2009; 302: 412-423
        • Clarke R.
        • Peden J.F.
        • Hopewell J.C.
        • Kyriakou T.
        • Goel A.
        • Heath S.C.
        • Parish S.
        • Barlera S.
        • Franzosi M.G.
        • Rust S.
        • Bennett D.
        • Silveira A.
        • Malarstig A.
        • Green F.R.
        • Lathrop M.
        • Gigante B.
        • Leander K.
        • de Faire U.
        • Seedorf U.
        • Hamsten A.
        • Collins R.
        • Watkins H.
        • Farrall M.
        • PROCARDIS Consortium
        Genetic variants associated with Lp(a) lipoprotein level and coronary disease.
        N. Engl. J. Med. 2009; 361: 2518-2528
        • Kamstrup P.R.
        • Tybjaerg-Hansen A.
        • Steffensen R.
        • Nordestgaard B.G.
        Genetically elevated lipoprotein(a) and increased risk of myocardial infarction.
        J. Am. Med. Assoc. 2009; 301: 2331-2339
        • O'Donoghue M.L.
        • Fazio S.
        • Giugliano R.P.
        • Stroes E.S.G.
        • Kanevsky E.
        • Gouni-Berthold I.
        • Im K.
        • Lira Pineda A.
        • Wasserman S.M.
        • Ceska R.
        • Ezhov M.V.
        • Jukema J.W.
        • Jensen H.K.
        • Tokgozoglu S.L.
        • Mach F.
        • Huber K.
        • Sever P.S.
        • Keech A.C.
        • Pedersen T.R.
        • Sabatine M.S.
        Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk.
        Circulation. 2019; 139: 1483-1492
        • Burgess S.
        • Ference B.A.
        • Staley J.R.
        • Freitag D.F.
        • Mason A.M.
        • Nielsen S.F.
        • Willeit P.
        • Young R.
        • Surendran P.
        • Karthikeyan S.
        • Bolton T.R.
        • Peters J.E.
        • Kamstrup P.R.
        • Tybjaerg-Hansen A.
        • Benn M.
        • Langsted A.
        • Schnohr P.
        • Vedel-Krogh S.
        • Kobylecki C.J.
        • Ford I.
        • Packard C.
        • Trompet S.
        • Jukema J.W.
        • Sattar N.
        • Di Angelantonio E.
        • Saleheen D.
        • Howson J.M.M.
        • Nordestgaard B.G.
        • Butterworth A.S.
        • Danesh J.
        European Prospective Investigation into Cancer and Nutrition–Cardiovascular Disease (EPIC-CVD) Consortium. Association of LPA variants with risk of coronary disease and the implications for lipoprotein(a)-lowering therapies: a Mendelian randomization analysis.
        JAMA Cardiol. 2018; 3: 619-627
        • Parish S.
        • Hopewell J.C.
        • Hill M.R.
        • Marcovina S.
        • Valdes-Marquez E.
        • Haynes R.
        • Offer A.
        • Pedersen T.R.
        • Baigent C.
        • Collins R.
        • Landray M.
        • Armitage J.
        • HPS2-THRIVE Collaborative Group
        Impact of apolipoprotein(a) isoform size on lipoprotein(a) lowering in the HPS2-THRIVE Study.
        Circ Genom Precis Med. 2018; 11e001696
        • Langlois M.R.
        • Chapman M.J.
        • Cobbaert C.
        • Mora S.
        • Remaley A.T.
        • Ros E.
        • Watts G.F.
        • Borén J.
        • Baum H.
        • Bruckert E.
        • Catapano A.
        • Descamps O.S.
        • von Eckardstein A.
        • Kamstrup P.R.
        • Kolovou G.
        • Kronenberg F.
        • Langsted A.
        • Pulkki K.
        • Rifai N.
        • Sypniewska G.
        • Wiklund O.
        • Nordestgaard B.G.
        European Atherosclerosis Society (EAS) and the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) Joint Consensus Initiative. Quantifying atherogenic lipoproteins: current and future challenges in the era of personalized medicine and very low concentrations of LDL cholesterol. A consensus statement from EAS and EFLM.
        Clin. Chem. 2018; 64: 1006-1033
        • Jialal I.
        • Inn M.
        • Siegel D.
        • Devaraj S.
        Underestimation of low density lipoprotein-cholesterol with the Friedewald equation versus a direct homogenous low density lipoprotein-cholesterol assay.
        Lab. Med. 2017; 48: 220-224
        • Martin S.S.
        • Blaha M.J.
        • Elshazly M.B.
        • Brinton E.A.
        • Toth P.P.
        • McEvoy J.W.
        • Joshi P.H.
        • Kulkarni K.R.
        • Mize P.D.
        • Kwiterovich P.O.
        • Defilippis A.P.
        • Blumenthal R.S.
        • Jones S.R.
        Friedewald-estimated versus directly measured low-density lipoprotein cholesterol and treatment implications.
        J. Am. Coll. Cardiol. 2013; 62: 732-739
        • Nauck M.
        • Warnick G.R.
        • Rifai N.
        Methods for measurement of LDL-cholesterol: a critical assessment of direct measurement by homogeneous assays versus calculation.
        Clin. Chem. 2002; 48: 236-254
        • Razi F.
        • Forouzanfar K.
        • Bandarian F.
        • Nasli-Esfahani E.
        LDL-cholesterol measurement in diabetic type 2 patients: a comparison between direct assay and popular equations.
        J. Diabetes Metab. Disord. 2017; 16: 43
        • Robinson J.G.
        • Rosenson R.S.
        • Farnier M.
        • Chaudhari U.
        • Sasiela W.J.
        • Merlet L.
        • Miller K.
        • Kastelein J.J.
        Safety of very low low-density lipoprotein cholesterol levels with alirocumab: pooled data from randomized trials.
        J. Am. Coll. Cardiol. 2017; 69: 471-482
        • Sathiyakumar V.
        • Park J.
        • Golozar A.
        • Lazo M.
        • Quispe R.
        • Guallar E.
        • Blumenthal R.S.
        • Jones S.R.
        • Martin S.S.
        Fasting versus nonfasting and low-density lipoprotein cholesterol accuracy.
        Circulation. 2018; 137: 10-19
        • Whelton S.P.
        • Meeusen J.W.
        • Donato L.J.
        • Jaffe A.S.
        • Saenger A.
        • Sokoll L.J.
        • Blumenthal R.S.
        • Jones S.R.
        • Martin S.S.
        Evaluating the atherogenic burden of individuals with a Friedewald-estimated low-density lipoprotein cholesterol <70 mg/dL compared with a novel low-density lipoprotein estimation method.
        J Clin Lipidol. 2017; 11: 1065-1072
        • Meeusen J.W.
        • Lueke A.J.
        • Jaffe A.S.
        • Saenger A.K.
        Validation of a proposed novel equation for estimating LDL cholesterol.
        Clin. Chem. 2014; 60: 1519-1523
        • Langlois M.R.
        • Descamps O.S.
        • van der Laarse A.
        • Weykamp C.
        • Baum H.
        • Pulkki K.
        • von Eckardstein A.
        • De Bacquer D.
        • Borén J.
        • Wiklund O.
        • Laitinen P.
        • Oosterhuis W.P.
        • Cobbaert C.
        • EAS-EFLM Collaborative Project
        Clinical impact of direct HDLc and LDLc method bias in hypertriglyceridemia. A simulation study of the EAS-EFLM Collaborative Project Group.
        Atherosclerosis. 2014; 233: 83-90
        • Miida T.
        • Nishimura K.
        • Okamura T.
        • Hirayama S.
        • Ohmura H.
        • Yoshida H.
        • Miyashita Y.
        • Ai M.
        • Tanaka A.
        • Sumino H.
        • Murakami M.
        • Inoue I.
        • Kayamori Y.
        • Nakamura M.
        • Nobori T.
        • Miyazawa Y.
        • Teramoto T.
        • Yokoyama S.
        A multicenter study on the precision and accuracy of homogeneous assays for LDL-cholesterol: comparison with a beta-quantification method using fresh serum obtained from non-diseased and diseased subjects.
        Atherosclerosis. 2012; 225: 208-215
        • Miller W.G.
        • Myers G.L.
        • Sakurabayashi I.
        • Bachmann L.M.
        • Caudill S.P.
        • Dziekonski A.
        • Edwards S.
        • Kimberly M.M.
        • Korzun W.J.
        • Leary E.T.
        • Nakajima K.
        • Nakamura M.
        • Nilsson G.
        • Shamburek R.D.
        • Vetrovec G.W.
        • Warnick G.R.
        • Remaley A.T.
        Seven direct methods for measuring HDL and LDL cholesterol compared with ultracentrifugation reference measurement procedures.
        Clin. Chem. 2010; 56: 977-986
        • Marcovina S.M.
        • Albers J.J.
        Lipoprotein (a) measurements for clinical application.
        J. Lipid Res. 2016; 57: 526-537
        • Marcovina S.M.
        • Koschinsky M.L.
        • Albers J.J.
        • Skarlatos S.
        Report of the national heart, lung, and blood institute workshop on lipoprotein(a) and cardiovascular disease: recent advances and future directions.
        Clin. Chem. 2003; 49: 1785-1796
        • Tsimikas S.
        • Fazio S.
        • Viney N.J.
        • Xia S.
        • Witztum J.L.
        • Marcovina S.M.
        Relationship of lipoprotein(a) molar concentrations and mass according to lipoprotein(a) thresholds and apolipoprotein(a) isoform size.
        J Clin Lipidol. 2018; 12: 1313-1323
        • Mora S.
        • Rifai N.
        • Buring J.E.
        • Ridker P.M.
        Fasting compared with nonfasting lipids and apolipoproteins for predicting incident cardiovascular events.
        Circulation. 2008; 118: 993-1001
        • Jorgensen A.B.
        • Frikke-Schmidt R.
        • West A.S.
        • Grande P.
        • Nordestgaard B.G.
        • Tybjaerg-Hansen A.
        Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction.
        Eur. Heart J. 2013; 34: 1826-1833
        • Kolovou G.D.
        • Mikhailidis D.P.
        • Kovar J.
        • Lairon D.
        • Nordestgaard B.G.
        • Ooi T.C.
        • Perez-Martinez P.
        • Bilianou H.
        • Anagnostopoulou K.
        • Panotopoulos G.
        Assessment and clinical relevance of non-fasting and postprandial triglycerides: an expert panel statement.
        Curr. Vasc. Pharmacol. 2011; 9: 258-270
        • Mihas C.
        • Kolovou G.D.
        • Mikhailidis D.P.
        • Kovar J.
        • Lairon D.
        • Nordestgaard B.G.
        • Ooi T.C.
        • Perez-Martinez P.
        • Bilianou H.
        • Anagnostopoulou K.
        • Panotopoulos G.
        Diagnostic value of postprandial triglyceride testing in healthy subjects: a meta-analysis.
        Curr. Vasc. Pharmacol. 2011; 9: 271-280
        • Nordestgaard B.G.
        • Varbo A.
        Triglycerides and cardiovascular disease.
        Lancet. 2014; 384: 626-635
        • Baca A.M.
        • Warnick G.R.
        Estimation of LDL-associated apolipoprotein B from measurements of triglycerides and total apolipoprotein B.
        Clin. Chem. 2008; 54: 907-910
        • Chapman M.J.
        • Ginsberg H.N.
        • Amarenco P.
        • Andreotti F.
        • Borén J.
        • Catapano A.L.
        • Descamps O.S.
        • Fisher E.
        • Kovanen P.T.
        • Kuivenhoven J.A.
        • Lesnik P.
        • Masana L.
        • Nordestgaard B.G.
        • Ray K.K.
        • Reiner Z.
        • Taskinen M.R.
        • Tokgözoglu L.
        • Tybjærg-Hansen A.
        • Watts G.F.
        European Atherosclerosis Society Consensus Panel. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management.
        Eur. Heart J. 2011; 32: 1345-1361
        • Cartier L.J.
        • Collins C.
        • Lagace M.
        • Douville P.
        Comparison of fasting and non-fasting lipid profiles in a large cohort of patients presenting at a community hospital.
        Clin. Biochem. 2018; 52: 61-66
        • National Clinical Guideline Centre (UK)
        Lipid Modification: Cardiovascular Risk Assessment and the Modification of Blood Lipids for the Primary and Secondary Prevention of Cardiovascular Disease.
        National Institute for Health and Care Excellence, London2014 (UK)
        • Joint British Societies Board
        Joint British Societies' consensus recommendations for the prevention of cardiovascular disease (JBS3).
        Heart. 2014; 100: ii1-ii67
        • Doran B.
        • Guo Y.
        • Xu J.
        • Weintraub H.
        • Mora S.
        • Maron D.J.
        • Bangalore S.
        Prognostic value of fasting versus nonfasting low-density lipoprotein cholesterol levels on long-term mortality: insight from the National Health and Nutrition Examination Survey III (NHANES-III).
        Circulation. 2014; 130: 546-553
        • Harari G.
        • Green M.S.
        • Magid A.
        • Zelber-Sagi S.
        Usefulness of non-high-density lipoprotein cholesterol as a predictor of cardiovascular disease mortality in men in 22-year follow-up.
        Am. J. Cardiol. 2017; 119: 1193-1198
        • Gu X.
        • Yang X.
        • Li Y.
        • Cao J.
        • Li J.
        • Liu X.
        • Chen J.
        • Shen C.
        • Yu L.
        • Huang J.
        • Gu D.
        Usefulness of low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol as predictors of cardiovascular disease in Chinese.
        Am. J. Cardiol. 2015; 116: 1063-1070
        • van den Berg M.J.
        • van der Graaf Y.
        • de Borst G.J.
        • Kappelle L.J.
        • Nathoe H.M.
        • Visseren F.L.J.
        • SMART Study Group
        Low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, triglycerides, and apolipoprotein B and cardiovascular risk in patients with manifest arterial disease.
        Am. J. Cardiol. 2016; 118: 804-810
        • van Deventer H.E.
        • Miller W.G.
        • Myers G.L.
        • Sakurabayashi I.
        • Bachmann L.M.
        • Caudill S.P.
        • Dziekonski A.
        • Edwards S.
        • Kimberly M.M.
        • Korzun W.J.
        • Leary E.T.
        • Nakajima K.
        • Nakamura M.
        • Shamburek R.D.
        • Vetrovec G.W.
        • Warnick G.R.
        • Remaley A.T.
        Non-HDL cholesterol shows improved accuracy for cardiovascular risk score classification compared to direct or calculated LDL cholesterol in a dyslipidemic population.
        Clin. Chem. 2011; 57: 490-501
        • Sniderman A.D.
        • Islam S.
        • Yusuf S.
        • McQueen M.J.
        Discordance analysis of apolipoprotein B and non-high density lipoprotein cholesterol as markers of cardiovascular risk in the INTERHEART study.
        Atherosclerosis. 2012; 225: 444-449
        • Cook N.R.
        • Mora S.
        • Ridker P.M.
        Lipoprotein(a) and cardiovascular risk prediction among women.
        J. Am. Coll. Cardiol. 2018; 72: 287-296
        • Kamstrup P.R.
        • Tybjaerg-Hansen A.
        • Nordestgaard B.G.
        Extreme lipoprotein(a) levels and improved cardiovascular risk prediction.
        J. Am. Coll. Cardiol. 2013; 61: 1146-1156
        • Willeit P.
        • Kiechl S.
        • Kronenberg F.
        • Witztum J.L.
        • Santer P.
        • Mayr M.
        • Xu Q.
        • Mayr A.
        • Willeit J.
        • Tsimikas S.
        Discrimination and net reclassification of cardiovascular risk with lipoprotein(a): prospective 15-year outcomes in the Bruneck Study.
        J. Am. Coll. Cardiol. 2014; 64: 851-860
        • European Association for Cardiovascular Prevention & Rehabilitation
        • Reiner Z.
        • Catapano A.L.
        • De Backer G.
        • Graham I.
        • Taskinen M.R.
        • Wiklund O.
        • Agewall S.
        • Alegria E.
        • Chapman M.J.
        • Durrington P.
        • Erdine S.
        • Halcox J.
        • Hobbs R.
        • Kjekshus J.
        • Filardi P.P.
        • Riccardi G.
        • Storey R.F.
        • Wood D.
        ESC Committee for practice guidelines Committees (CPG) 2008-2010 and 2010-2012 Committees. ESC/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European society of Cardiology (ESC) and the European atherosclerosis society (EAS).
        Eur. Heart J. 2011; 32: 1769-1818
        • Lloyd-Jones D.M.
        • Morris P.B.
        • Ballantyne C.M.
        • Birtcher K.K.
        • Daly Jr., D.D.
        • DePalma S.M.
        • Minissian M.B.
        • Orringer C.E.
        • Smith Jr., S.C.
        Focused update of the 2016 ACC expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology task force on expert consensus decision pathways.
        J. Am. Coll. Cardiol. 2017; 70 (2017): 1785-1822
        • Navarese E.P.
        • Robinson J.G.
        • Kowalewski M.
        • Kolodziejczak M.
        • Andreotti F.
        • Bliden K.
        • Tantry U.
        • Kubica J.
        • Raggi P.
        • Gurbel P.A.
        Association between baseline LDL-C level and total and cardiovascular mortality after LDL-C lowering: a systematic review and meta-analysis.
        J. Am. Med. Assoc. 2018; 319: 1566-1579
        • Hsia J.
        • MacFadyen J.G.
        • Monyak J.
        • Ridker P.M.
        Cardiovascular event reduction and adverse events among subjects attaining low-density lipoprotein cholesterol <50 mg/dl with rosuvastatin. The JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin).
        J. Am. Coll. Cardiol. 2011; 57: 1666-1675
        • McCormack T.
        • Dent R.
        • Blagden M.
        Very low LDL-C levels may safely provide additional clinical cardiovascular benefit: the evidence to date.
        Int. J. Clin. Pract. 2016; 70: 886-897
        • Williams B.
        • Mancia G.
        • Spiering W.
        • Agabiti Rosei E.
        • Azizi M.
        • Burnier M.
        • Clement D.L.
        • Coca A.
        • de Simone G.
        • Dominiczak A.
        • Kahan T.
        • Mahfoud F.
        • Redon J.
        • Ruilope L.
        • Zanchetti A.
        • Kerins M.
        • Kjeldsen S.E.
        • Kreutz R.
        • Laurent S.
        • Lip G.Y.H.
        • McManus R.
        • Narkiewicz K.
        • Ruschitzka F.
        • Schmieder R.E.
        • Shlyakhto E.
        • Tsioufis C.
        • Aboyans V.
        • Desormais I.
        • Authors/Task Force Members
        ESC/ESH guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European society of Cardiology and the European society of hypertension: the task force for the management of arterial hypertension of the European society of Cardiology and the European society of hypertension.
        J. Hypertens. 2018; 36 (2018): 1953-2041
        • Sabatine M.S.
        • Giugliano R.P.
        • Keech A.C.
        • Honarpour N.
        • Wiviott S.D.
        • Murphy S.A.
        • Kuder J.F.
        • Wang H.
        • Liu T.
        • Wasserman S.M.
        • Sever P.S.
        • Pedersen T.R.
        FOURIER Steering Committee and Investigators. Evolocumab and clinical outcomes in patients with cardiovascular disease.
        N. Engl. J. Med. 2017; 376: 1713-1722
        • Schwartz G.G.
        • Steg P.G.
        • Szarek M.
        • Bhatt D.L.
        • Bittner V.A.
        • Diaz R.
        • Edelberg J.M.
        • Goodman S.G.
        • Hanotin C.
        • Harrington R.A.
        • Jukema J.W.
        • Lecorps G.
        • Mahaffey K.W.
        • Moryusef A.
        • Pordy R.
        • Quintero K.
        • Roe M.T.
        • Sasiela W.J.
        • Tamby J.F.
        • Tricoci P.
        • White H.D.
        • Zeiher A.M.
        ODYSSEY OUTCOMES Committees and Investigators. Alirocumab and cardiovascular outcomes after acute coronary syndrome.
        N. Engl. J. Med. 2018; 379: 2097-2107
        • Charlton-Menys V.
        • Betteridge D.J.
        • Colhoun H.
        • Fuller J.
        • France M.
        • Hitman G.A.
        • Livingstone S.J.
        • Neil H.A.
        • Newman C.B.
        • Szarek M.
        • DeMicco D.A.
        • Durrington P.N.
        Targets of statin therapy: LDL cholesterol, non-HDL cholesterol, and apolipoprotein B in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS).
        Clin. Chem. 2009; 55: 473-480
        • Thompson A.
        • Danesh J.
        Associations between apolipoprotein B, apolipoprotein AI, the apolipoprotein B/AI ratio and coronary heart disease: a literature-based meta-analysis of prospective studies.
        J. Intern. Med. 2006; 259: 481-492
        • Thanassoulis G.
        • Williams K.
        • Ye K.
        • Brook R.
        • Couture P.
        • Lawler P.R.
        • de Graaf J.
        • Furberg C.D.
        • Sniderman A.
        Relations of change in plasma levels of LDL-C, non-HDL-C and apoB with risk reduction from statin therapy: a meta-analysis of randomized trials.
        J Am Heart Assoc. 2014; 3e000759
        • Robinson J.G.
        • Wang S.
        • Smith B.J.
        • Jacobson T.A.
        Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk.
        J. Am. Coll. Cardiol. 2009; 53: 316-322
        • Dalen J.E.
        • Devries S.
        Diets to prevent coronary heart disease 1957-2013: what have we learned?.
        Am. J. Med. 2014; 127: 364-369
        • Eckel R.H.
        • Jakicic J.M.
        • Ard J.D.
        • de Jesus J.M.
        • Houston Miller N.
        • Hubbard V.S.
        • Lee I.M.
        • Lichtenstein A.H.
        • Loria C.M.
        • Millen B.E.
        • Nonas C.A.
        • Sacks F.M.
        • Smith Jr., S.C.
        • Svetkey L.P.
        • Wadden T.A.
        • Yanovski S.Z.
        • Kendall K.A.
        • Morgan L.C.
        • Trisolini M.G.
        • Velasco G.
        • Wnek J.
        • Anderson J.L.
        • Halperin J.L.
        • Albert N.M.
        • Bozkurt B.
        • Brindis R.G.
        • Curtis L.H.
        • DeMets D.
        • Hochman J.S.
        • Kovacs R.J.
        • Ohman E.M.
        • Pressler S.J.
        • Sellke F.W.
        • Shen W.K.
        • Smith Jr., S.C.
        • Tomaselli G.F.
        American College of Cardiology/American heart association task force on practice guidelines. 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American heart association task force on practice guidelines.
        Circulation. 2014; 129: S76-S99
        • Mente A.
        • de Koning L.
        • Shannon H.S.
        • Anand S.S.
        A systematic review of the evidence supporting a causal link between dietary factors and coronary heart disease.
        Arch. Intern. Med. 2009; 169: 659-669
        • Chowdhury R.
        • Warnakula S.
        • Kunutsor S.
        • Crowe F.
        • Ward H.A.
        • Johnson L.
        • Franco O.H.
        • Butterworth A.S.
        • Forouhi N.G.
        • Thompson S.G.
        • Khaw K.T.
        • Mozaffarian D.
        • Danesh J.
        • Di Angelantonio E.
        Association of dietary, circulating, and supplement fatty acids with coronary risk: a systematic review and meta-analysis.
        Ann. Intern. Med. 2014; 160: 398-406
        • Mozaffarian D.
        • Micha R.
        • Wallace S.
        Effects on coronary heart disease of increasing polyunsaturated fat in place of saturated fat: a systematic review and meta-analysis of randomized controlled trials.
        PLoS Med. 2010; 7e1000252
        • Forouhi N.G.
        • Krauss R.M.
        • Taubes G.
        • Willett W.
        Dietary fat and cardiometabolic health: evidence, controversies, and consensus for guidance.
        BMJ. 2018; 361: k2139
        • Mozaffarian D.
        Natural trans fat, dairy fat, partially hydrogenated oils, and cardiometabolic health: the Ludwigshafen Risk and Cardiovascular Health Study.
        Eur. Heart J. 2016; 37: 1079-1081
        • Chen M.
        • Li Y.
        • Sun Q.
        • Pan A.
        • Manson J.E.
        • Rexrode K.M.
        • Willett W.C.
        • Rimm E.B.
        • Hu F.B.
        Dairy fat and risk of cardiovascular disease in 3 cohorts of US adults.
        Am. J. Clin. Nutr. 2016; 104: 1209-1217
        • Moore T.J.
        • Vollmer W.M.
        • Appel L.J.
        • Sacks F.M.
        • Svetkey L.P.
        • Vogt T.M.
        • Conlin P.R.
        • Simons-Morton D.G.
        • Carter-Edwards L.
        • Harsha D.W.
        Effect of dietary patterns on ambulatory blood pressure : results from the dietary approaches to stop hypertension (DASH) trial. DASH collaborative research group.
        Hypertension. 1999; 34: 472-477
        • Sofi F.
        • Macchi C.
        • Abbate R.
        • Gensini G.F.
        • Casini A.
        Mediterranean diet and health status: an updated meta-analysis and a proposal for a literature-based adherence score.
        Public Health Nutr. 2014; 17: 2769-2782
        • Grosso G.
        • Marventano S.
        • Yang J.
        • Micek A.
        • Pajak A.
        • Scalfi L.
        • Galvano F.
        • Kales S.N.
        A comprehensive meta-analysis on evidence of Mediterranean diet and cardiovascular disease: are individual components equal?.
        Crit. Rev. Food Sci. Nutr. 2017; 57: 3218-3232
        • de Lorgeril M.
        • Salen P.
        • Martin J.L.
        • Monjaud I.
        • Delaye J.
        • Mamelle N.
        Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study.
        Circulation. 1999; 99: 779-785
        • Estruch R.
        • Ros E.
        • Salas-Salvadó J.
        • Covas M.I.
        • Corella D.
        • Arós F.
        • Gómez-Gracia E.
        • Ruiz-Gutiérrez V.
        • Fiol M.
        • Lapetra J.
        • Lamuela-Raventos R.M.
        • Serra-Majem L.
        • Pintó X.
        • Basora J.
        • Muñoz M.A.
        • Sorlí J.V.
        • Martínez J.A.
        • Martínez-González M.A.
        Retraction and republication: primary prevention of cardiovascular disease with a Mediterranean diet.
        N. Engl. J. Med. 2018; 378: 2441-2442
        • Brown L.
        • Rosner B.
        • Willett W.W.
        • Sacks F.M.
        Cholesterol-lowering effects of dietary fiber: a meta-analysis.
        Am. J. Clin. Nutr. 1999; 69: 30-42
        • Gylling H.
        • Plat J.
        • Turley S.
        • Ginsberg H.N.
        • Ellegård L.
        • Jessup W.
        • Jones P.J.
        • Lütjohann D.
        • Maerz W.
        • Masana L.
        • Silbernagel G.
        • Staels B.
        • Borén J.
        • Catapano A.L.
        • De Backer G.
        • Deanfield J.
        • Descamps O.S.
        • Kovanen P.T.
        • Riccardi G.
        • Tokgözoglu L.
        • Chapman M.J.
        European Atherosclerosis Society Consensus Panel on Phytosterols. Plant sterols and plant stanols in the management of dyslipidaemia and prevention of cardiovascular disease.
        Atherosclerosis. 2014; 232: 346-360
        • Musa-Veloso K.
        • Poon T.H.
        • Elliot J.A.
        • Chung C.
        A comparison of the LDL-cholesterol lowering efficacy of plant stanols and plant sterols over a continuous dose range: results of a meta-analysis of randomized, placebo-controlled trials.
        Prostaglandins Leukot. Essent. Fatty Acids. 2011; 85: 9-28
        • Poli A.
        • Barbagallo C.M.
        • Cicero A.F.G.
        • Corsini A.
        • Manzato E.
        • Trimarco B.
        • Bernini F.
        • Visioli F.
        • Bianchi A.
        • Canzone G.
        • Crescini C.
        • de Kreutzenberg S.
        • Ferrara N.
        • Gambacciani M.
        • Ghiselli A.
        • Lubrano C.
        • Marelli G.
        • Marrocco W.
        • Montemurro V.
        • Parretti D.
        • Pedretti R.
        • Perticone F.
        • Stella R.
        • Marangoni F.
        Nutraceuticals and functional foods for the control of plasma cholesterol levels. An intersociety position paper.
        Pharmacol. Res. 2018; 134: 51-60
        • Li Y.
        • Jiang L.
        • Jia Z.
        • Xin W.
        • Yang S.
        • Yang Q.
        • Wang L.
        A meta-analysis of red yeast rice: an effective and relatively safe alternative approach for dyslipidemia.
        PLoS One. 2014; 9e98611
        • Lu Z.
        • Kou W.
        • Du B.
        • Wu Y.
        • Zhao S.
        • Brusco O.A.
        • Morgan J.M.
        • Capuzzi D.M.
        Chinese Coronary Secondary Prevention Study Group, Li S. Effect of Xuezhikang, an extract from red yeast Chinese rice, on coronary events in a Chinese population with previous myocardial infarction.
        Am. J. Cardiol. 2008; 101: 1689-1693
        • Zomer E.
        • Gurusamy K.
        • Leach R.
        • Trimmer C.
        • Lobstein T.
        • Morris S.
        • James W.P.
        • Finer N.
        Interventions that cause weight loss and the impact on cardiovascular risk factors: a systematic review and meta-analysis.
        Obes. Rev. 2016; 17: 1001-1011
        • Shaw K.
        • Gennat H.
        • O'Rourke P.
        • Del Mar C.
        Exercise for overweight or obesity.
        Cochrane Database Syst. Rev. 2006; 4: CD003817
        • Rimm E.B.
        • Williams P.
        • Fosher K.
        • Criqui M.
        • Stampfer M.J.
        Moderate alcohol intake and lower risk of coronary heart disease: meta-analysis of effects on lipids and haemostatic factors.
        BMJ. 1999;